Comparative evaluation of two commercial amplification assays for direct detection of Mycobacterium tuberculosis complex in respiratory specimens

Two commercial assays detecting the presence of Mycobacterium tuberculosis complex in clinical specimens by rRNA target amplification (Gen-Probe Amplified M. tuberculosis Direct Test [AMTD]) and PCR (Amplicor) were evaluated, The tests were applied to 327 digested, decontaminated respiratory specimens collected from 236 patients, Results were compared with those of acid-fast staining and culture, The combination of culture and clinical diagnosis was considered the ''gold standard.'' A total of 60 specimens were collected from 27 patients with a diagnosis of pulmonary tuberculosis, Thirteen of these specimens were from patients receiving standard antituberculosis therapy and therefore were not included in the comparison, Of the remaining 47 specimens, 33 were smear positive, 40 were culture positive, 45 were AMTD positive, and 39 were Amplicor positive, After resolution of discrepant results, the overall sensitivities, specificities, and positive and negative predictive values were 77, 100, 100, and 95 for staining; 87, 100, 100, and 97.4 for culture; 95.9, 98.9, 94, and 99.2 for AMTD; and 85.4, 99.6, 97.9, and 97.1 for Amplicor, respectively, Agreement between AMTD and Amplicor assay results was 96.8%, It is concluded that although both nucleic acid amplification methods are rapid and specific for the detection of M. tuberculosis complex in respiratory specimens, AMTD appeared to be more sensitive than Amplicor.